
Opinion|Videos|April 26, 2024
TIVO-3: Tivozanib vs Sorafenib in Advanced Renal Cell Carcinoma
Sumanta Kumar Pal, MD, FASCO, reviews data from the TIVO-3 study investigating tivozanib in patients with advanced renal cell carcinoma, and the panel offers its impressions on the results.
Episodes in this series









































